|
Initiative antibiotic types
|
|
Second-generation cephalosporins
|
10 (9.9%)
|
3 (6.5%)
|
4 (17.4%)
|
3 (9.4%)
|
0.353
|
|
Third-generation cephalosporins (without enzyme inhibitors)
|
31 (30.7%)
|
18 (39.1%)
|
5 (21.7%)
|
8 (25.1%)
|
0.235
|
|
Third-generation cephalosporins (with enzyme inhibitors)
|
22 (21.8%)
|
5 (10.9%)
|
11 (47.8%)
|
6 (18.8%)
|
0.002
|
|
4th-generation cephalosporin
|
1 (1%)
|
0 (0)
|
0 (0)
|
1 (3.1%)
|
0.545
|
|
Carbapenems
|
31 (30.7%)
|
17 (37%)
|
1 (4.3%)
|
13 (40.6%)
|
0.007
|
|
Quinolones
|
7 (7%)
|
2 (4.3%)
|
3 (13%)
|
2 (6.3%)
|
0.469
|
|
Glycopeptides
|
4 (4%)
|
2 (4.3%)
|
0 (0)
|
2 (6.3%)
|
0.685
|
|
Clindamycin
|
1 (1%)
|
1 (2.2%)
|
0 (0)
|
0 (0)
|
1.000
|
|
Antibiotics need to be upgraded
|
32 (31.7%)
|
7 (15.2%)
|
8 (34.8%)
|
17 (53.1%)
|
0.002
|
|
Upgrade M (IQR) on the X-day of admission
|
6 (3.5–7)
|
5 (3–7)
|
6 (4–10)
|
6.5 (3.0–7.5)
|
0.259
|
|
Number of antibiotic upgrades M (IQR)
|
0 (0–1)
|
0 (0–0)
|
0 (0–1)
|
1 (0–2)
|
0.001
|
|
Antifungal therapy
|
32 (31.7%)
|
6 (13.0%)
|
6 (26.1%)
|
20 (62.5%)
|
< 0.001
|
|
Fluconazole is preferred
|
17 (16.8%)
|
3 (6.5%)
|
5 (21.7%)
|
9 (28.1%)
|
0.032
|
|
Upgrading ratio of antifungal drugs
|
3 (9.38%)
|
0 (0)
|
1 (16.7%)
|
2 (10%)
|
1.000
|
|
Upgrade M (IQR) on the X-day of admission
|
8.5 (5–15.5)
|
5.5 (4–13)
|
7 (7–10)
|
11.5 (5.5–20)
|
0.407
|
|
Upgrading times of antifungal agents M (IQR)
|
1 (1–1)
|
-
|
1
|
1
|
-
|
|
Need parenteral nutrition support
|
26 (25.7%)
|
6 (13%)
|
6 (26.1%)
|
14 (43.8%)
|
0.010
|
|
Use of glucocorticoids
|
12 (11.9%)
|
5 (10.9%)
|
1 (4.3%)
|
6 (18.8%)
|
0.255
|
|
Intravenous glucocorticoid
|
9 (8.91%)
|
2 (4.3%)
|
1 (4.3%)
|
6 (18.8%)
| |
|
Oral glucocorticoid
|
3 (2.97%)
|
3 (6.5%)
|
0
|
0
|
0.086
|
|
Not used
|
89 (88.12%)
|
41 (89.1%)
|
22 (95.7%)
|
26 (81.3%)
| |
|
Tracheal intubation/incision
|
9 (8.9%)
|
2 (4.3%)
|
1 (4.3%)
|
6 (18.8%)
|
0.061
|
